Member Bios: Racine, Rein, Ryan, Seligmann

Eric Racine is the vice president for Partners in Patient Health, North American corporate affairs of Sanofi. His department is responsible for partnerships with patients and health advocates to address issues critical to improving health. Before he joined the pharmaceutical industry, Eric held various academic, clinical and management positions. He has a doctor of pharmacy degree from Wayne State University in Michigan and an executive MBA from Rutgers University.

Jeffrey Rein is the retired chairman and chief executive officer for Walgreens, the nation’s largest drugstore chain. He joined the company as an assistant store manager in 1982. After several increasingly resposible positons,  in 2006 he became CEO .He's a UA graduate, earning his accounting degree in 1974 and his pharmacy degree in 1980, He serves on the board of directors for the Meijer Company, Midtown Educational Foundation, Midwest Young Artists and University of Arizona Eller College National Advisory Board.

Mary J. Ryan worked for Medco Health Solutions, Inc., from 1988 until 2012. She is retired as vice president, corporate regulatory group,  responsible for interface with various regulatory agencies, including state boards of pharmacy and departments of insurance. Mary graduated from UA with a bachelor of science in pharmacy in 1974. She completed her master’s degree in business administration at Arizona State University in 1983. She is a member of the American Pharmacists Association and the chair of the Legislative and Regulatory Action Committee at the Academy of Managed Care Pharmacy.

Bruce Seligmann is the founder, director, chief science officer and vice president of research and development at High Throughput Genomics based in Tucson. Through his work, Bruce has provided time-and cost-saving technology that assists the advancement of research, drug discovery and the development of better therapies and diagnostics.  Bruce is also the founder of Systems Integration Drug Discovery Co., which was sold to Discovery Partners International. Before that, he was the vice president of research and development and the center director at the biotech company Selectide.